LEMAITRE VASCULAR INC (LMAT) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR LEMAITRE VASCULAR INC (LMAT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
LEMAITRE VASCULAR INC Q3 2025 10-Q Analysis
Risk Factors
- • New product recall risk triggered by April 2025 inadequate seal issue on TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters packaging
- • Updated regulatory risk: August 2025 FDA warning letter to Artegraft facility, no material financial impact or sales disruption reported
LEMAITRE VASCULAR INC Q3 2025 Quarterly FinancialsXBRL
Revenue
$61M
▲ +11.4% YoY▼ -5.0% QoQ
Net Income
$17M
▲ +55.8% YoY▲ +26.0% QoQ
Gross Margin
75.3%
▲ +746bp YoY▲ +526bp QoQ
Operating Margin
33.3%
▲ +929bp YoY▲ +814bp QoQ
Net Margin
28.4%
▲ +812bp YoY▲ +699bp QoQ
ROE
4.6%
Total Assets
$598M
EPS (Diluted)
$0.76
▲ +55.1% YoY▲ +26.7% QoQ
Operating Cash Flow
$29M
▲ +101.9% YoY▲ +41.8% QoQ
Source: XBRL data from LEMAITRE VASCULAR INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on LEMAITRE VASCULAR INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.